Secondary analysis (exit interviews) of a phase 3 trial in 30 patients with short bowel syndrome with intestinal failure: 73% (16/22) on glepaglutide vs 25% (2/8) on placebo reported better health-related quality of life; descriptive, small numbers.
Secondary analysisn = 30
Mercer et al. Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial